Rabies Repurposed Drug

FNDR is developing a therapeutic intervention for symptomatic rabies by repurposing a clinically approved molecule with a well-established safety profile. Preclinical studies have demonstrated antiviral activity in vitro and improved survival in a murine rabies model. A clinical trial is being planned in collaboration with major Indian hospitals to assess efficacy in human patients. This program addresses a critical gap in treatment for a universally fatal neglected disease.